cerc-301
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2007 (NCT00472576)
Timeline
Indications
Mechanism of action
- Glutamate NMDA receptor; GRIN1/GRIN2BANTAGONIST
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
Non-competitive antagonist, negative modulator.
GRIN2B selective.
Binds to ifenprodil site on N-terminal domain.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1- Mol. weight
- 358.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2068839 ↗
Also known as
- 4-methylbenzyl 3-fluoro-4-((pyrimidin-2-ylamino)methyl)piperidine-1-carboxylate
- cerc-301
- cerc-301
- cerc-301
- cerc-301
- mk0657
- mk-0657
- mk-0657
- mk-0657
- mk-0657
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02459236 | Phase 2 | Jun 1, 2015 | Cerecor Inc |
| NCT01941043 | Phase 2 | Nov 1, 2013 | Cerecor Inc |
| NCT00472576 | Phase 1 | May 1, 2007 | National Institute of Mental Health (NIMH), National Institutes of Health (NIH) |
| NCT00505843 | Phase 1 | May 1, 2007 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cerecor Inc | For profit | 2 | 2 | 1 | 2013 |
| Merck | For profit | 1 | 1 | 1 | 2007 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2007 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1